WO2007149686A3 - Protéines stabilisées - Google Patents

Protéines stabilisées Download PDF

Info

Publication number
WO2007149686A3
WO2007149686A3 PCT/US2007/069948 US2007069948W WO2007149686A3 WO 2007149686 A3 WO2007149686 A3 WO 2007149686A3 US 2007069948 W US2007069948 W US 2007069948W WO 2007149686 A3 WO2007149686 A3 WO 2007149686A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
proteins
methods
oxidizable amino
disclosed
Prior art date
Application number
PCT/US2007/069948
Other languages
English (en)
Other versions
WO2007149686A2 (fr
Inventor
Stephen K Youngster
Amartya Basu
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Priority to CA002653061A priority Critical patent/CA2653061A1/fr
Priority to JP2009516623A priority patent/JP2010500963A/ja
Priority to EP07797875A priority patent/EP2038424A2/fr
Publication of WO2007149686A2 publication Critical patent/WO2007149686A2/fr
Publication of WO2007149686A3 publication Critical patent/WO2007149686A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des méthodes de stabilisation de protéines comportant au moins un acide aminé oxydable, telles que l'adénosine désaminase humaine recombinante (rhADA). Les méthodes incluent le traitement d'une protéine contenant un acide aminé oxydable avec une quantité suffisante d'un agent coiffant tel qu'une glutathione dans des conditions réactionnelles suffisantes pour coiffer l'acide aminé oxydable sans inactiver de façon significative la protéine. La présente invention porte également sur des protéines coiffées stabilisées, des conjugués polymères de protéines coiffées et des méthodes de traitement employant lesdites méthodes.
PCT/US2007/069948 2006-06-21 2007-05-30 Protéines stabilisées WO2007149686A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002653061A CA2653061A1 (fr) 2006-06-21 2007-05-30 Proteines stabilisees
JP2009516623A JP2010500963A (ja) 2006-06-21 2007-05-30 安定化タンパク質
EP07797875A EP2038424A2 (fr) 2006-06-21 2007-05-30 Proteines stabilisees

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80541706P 2006-06-21 2006-06-21
US60/805,417 2006-06-21
US73801207A 2007-04-20 2007-04-20
US11/738,012 2007-04-20

Publications (2)

Publication Number Publication Date
WO2007149686A2 WO2007149686A2 (fr) 2007-12-27
WO2007149686A3 true WO2007149686A3 (fr) 2009-04-02

Family

ID=38834219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/069948 WO2007149686A2 (fr) 2006-06-21 2007-05-30 Protéines stabilisées

Country Status (5)

Country Link
EP (1) EP2038424A2 (fr)
JP (1) JP2010500963A (fr)
CA (1) CA2653061A1 (fr)
TW (1) TW200817521A (fr)
WO (1) WO2007149686A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009011320A (es) 2007-04-20 2009-12-15 Enzon Pharmaceuticals Inc Terapia anticancer enzimatica.
MX2009011319A (es) * 2007-04-20 2009-12-11 Enzon Pharmaceuticals Inc Adenosina desaminasa recombinante estable.
WO2010033207A1 (fr) 2008-09-19 2010-03-25 Nektar Therapeutics Conjugués polymères de peptides thérapeutiques
EP2344200A2 (fr) * 2008-09-19 2011-07-20 Nektar Therapeutics Peptides thérapeutiques modifiés, procédés pour les préparer et les utiliser
JP5564517B2 (ja) * 2009-02-20 2014-07-30 ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ グルタチオンをベースとする薬物送達システム
US9121016B2 (en) * 2011-09-09 2015-09-01 Toyota Motor Engineering & Manufacturing North America, Inc. Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
US8911986B2 (en) * 2011-04-29 2014-12-16 Toyota Motor Engineering & Manufacturing North America, Inc. Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
KR102122463B1 (ko) 2014-10-14 2020-06-15 할로자임, 아이엔씨 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
WO2021022198A1 (fr) * 2019-08-01 2021-02-04 Carnegie Mellon University (CMU) Réglage de la solubilité de protéines par modification de surface polymère

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207876B1 (en) * 1998-04-28 2001-03-27 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6946098B2 (en) * 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207876B1 (en) * 1998-04-28 2001-03-27 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6946098B2 (en) * 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials

Also Published As

Publication number Publication date
WO2007149686A2 (fr) 2007-12-27
EP2038424A2 (fr) 2009-03-25
TW200817521A (en) 2008-04-16
JP2010500963A (ja) 2010-01-14
CA2653061A1 (fr) 2007-12-27

Similar Documents

Publication Publication Date Title
WO2007149686A3 (fr) Protéines stabilisées
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
WO2007094916A3 (fr) Polypeptides d'acides aminés non naturels présentant une immunogénicité modulée
WO2005118813A3 (fr) Acides nucleiques, polypeptides, methodes d'expression, et compositions immunogenes associees a la proteine spike du coronavirus sras
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
WO2007124698A3 (fr) Méthode de blocage d'une infection à flavivirus, molécules et utilisations associées
WO2006138099A3 (fr) Formulation de proteines de morphogenese osseuse
WO2007035716A3 (fr) Compositions de proteines rap specifiques des proteines contenant du cr, et leurs utilisations
WO2007046103A3 (fr) Systeme destine a l'administration transdermique iontophoretique d'agents polymeres et methodes d'utilisation de ce systeme
WO2006094974A3 (fr) Stabilisateur defini chimiquement
EP2628746A3 (fr) Procédé pour la concentration d'un polypeptide
WO2006050211A3 (fr) Therapie genique a base de proteine decarboxylase d'acide glutamique a administration peripherique pour lutter contre la douleur engendree par un traumatisme medullaire
WO2006096774A3 (fr) Composition et methodes de diffusion de monoxyde de carbone (co) et de monoxyde d'azote (no) dans un tissu en utilisant des proteines heme comme supports
WO2006101387A3 (fr) STRUCTURE HYBRIDE ß COMPRENANT DES PROTEINES DE LIAISON AMYLOIDES ET METHODES DE DETECTION DE LA STRUCTURE HYBRIDE ß POUR MODULER LA FORMATION DE FIBRILLES DANS LES STRUCTURES HYBRIDES ß ET MODULER LA TOXICITE INDUITE PAR LA STRUCTURE HYBRIDE ß, ET PROCEDE VISANT A CONTRARIER LA COAGULATION SANGUINE
WO2010017369A3 (fr) Diffusion et libération d’une macromolécule à partir d’hydrogels de peptides en épingle à cheveux b autoassemblés
WO2007097903A3 (fr) Peptides inhibiteurs de fusion du vih à propriétés biologiques améliorées
WO2004111081A3 (fr) Peptides antigeniques de coronavirus de sars, et utilisations
EP2447368A3 (fr) Nouveaux peptides pour traiter et prévenir les troubles de type immunitaire, y compris le traitement et la prévention des infections en modulant l'immunité innée
WO2007060213A3 (fr) Polypeptides d’erythropoietine et leurs utilisations
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2006047728A3 (fr) Genes bmp et proteines de fusion
WO2008040111A8 (fr) Nouveaux peptides pour le traitement et la prévention de troubles associés aux troubles immunitaires, comprenant le traitement et la prévention d'une infection par modulation de l'immunité innée
WO2005051902A3 (fr) Canal proteique mscl modifie
WO2004098536A3 (fr) Activite antivirale de peptides cathelicidiniques
WO2005059131A3 (fr) Proteine fixant des proteines en miniature et leurs applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07797875

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2653061

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009516623

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007797875

Country of ref document: EP